Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy

Ryan Bjordahl, PhD, John Goulding, PhD, Mochtar Pribadi, PhD, Robert Blum, MS, Chiawei Chang, Yijia Pan, PhD, Lucas Ferrari de Andrade, PhD, Kai W. Wucherpfennig, Yu-Waye Chu, MD, Hui-yi Chu, PhD, Wen-I Yeh, PhD, Svetlana Gaidarova, MS, Ellen Liu, PhD, Shohreh Sikaroodi, PhD, Lauren Fong, PhD, Janel Huffman, MS, Tom Lee, PhD, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141095

Published: 2020

Journal Articles

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Kate Dixon, PhD, Robert Hullsiek, Kristin Snyder, Zachary Davis, PhD BS, Melissa Khaw, Tom Lee, PhD, Hui-Yi Chu, PhD, Ramzey Abujarour, PhD, Jason Dinella, PhD, Paul Rogers, PhD, Ryan Bjordahl, PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD, Jianming Wu, PhD, Bruce Walcheck, PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-139760

Published: 2020

Journal Articles

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Karrune Woan, MD PhD, Zachary Davis, PhD BS, Greg Bonello, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Tom Lee, PhD, Martin Felices, PhD, Bruce Walcheck, PhD, Bruce R. Blazar, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 57–58.

https://doi.org/10.1182/blood-2020-137138

Published: 2020

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Jode P Goodridge, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, John Reiser, PhD, Svetlana Gaidarova, MS, Robert Blum, MS, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Yu-Waye Chu, MD, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Armin Rehm, Uta Hopken, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142750

Published: 2020

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Jode P Goodridge, PhD, Sajid Mahmood, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Jason Dinella, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Uta Hopken, Armin Rehm, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 3214.

https://doi.org/10.1182/blood-2019-131373

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

Dan S Kaufman, MD PhD, Ryan Bjordahl, PhD, Huang Zhu, PhD, Robert Blum, Andres Bahena, Sajid Mahmood, PhD, Greg Bonello, PhD, Tom Lee, PhD, Bruce Walcheck, PhD, Frank Cichocki, PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2018) 132 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2018-99-113701

Published: 2018

Journal Articles

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Dan S Kaufman, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 730.

https://doi.org/10.1182/blood-2018-99-114893

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Ryan Bjordahl, PhD, Raedun Clarke, PhD, Svetlana Gaidarova, Matthieu Bauer, PhD, Jeff Sasaki, Brian Groff, Tom Lee, PhD, Weijie Lan, PhD, Ramzey Abujarour, PhD, Greg Bonello, PhD, Megan Robinson, Ian Hardy, PhD, Daniel Shoemaker, PhD, Bahram Valamehr, PhD

Blood (2017) 130 (Supplement 1): 3187.

https://doi.org/10.1182/blood.V130.Suppl_1.3187.3187

Published: 2017

Journal Articles

Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy

Huang Zhu, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, Paul Rogers, Robert Blum, Dan Kaufman, MD, Bruce Walcheck, PhD, Bahram Valamehr, PhD

Blood (2017) 130 (Supplement 1): 4452.

https://doi.org/10.1182/blood.V130.Suppl_1.4452.4452

Published: 2017

Journal Articles

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood (2017) 130 (Supplement 1): 656.

https://doi.org/10.1182/blood.V130.Suppl_1.656.656

Published: 2017

Journal Articles

Engineering Human Induced Pluripotent Stem Cells with Novel Chimeric Antigen Receptors to Generate Natural Killer (NK) Cell Cancer Immunotherapies with Targeted Anti-Tumor Activity

Ye Ethan Ethan Li, MD, David Hermanson, PhD, Branden Moriarity, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, Bahram Valamehr, PhD, Dan Kaufman, MD

Blood (2017) 130 (Supplement 1): 1905.

https://doi.org/10.1182/blood.V130.Suppl_1.1905.1905

Published: 2017

Journal Articles

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Frank Cichocki, PhD, Bahram Valamehr, PhD MBA, Dhifaf Sarhan, PhD, Bin Zhang, Sarah Cooley, MD, Michael R. Verneris, MD, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Betsy Rezner, BS, Paul Rogers, PhD, Chad Green, David H McKenna, MD, Daniel Shoemaker, PhD, Scott Wolchko, MS, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 1225.

https://doi.org/10.1182/blood.V128.22.1225.1225

Published: 2016

Journal Articles

Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity

Blood (2016) 128 (22): 3363.

https://doi.org/10.1182/blood.V128.22.3363.3363

Published: 2016

NARROW

Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Engineering Human Induced Pluripotent Stem Cells with Novel Chimeric Antigen Receptors to Generate Natural Killer (NK) Cell Cancer Immunotherapies with Targeted Anti-Tumor Activity

Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function

Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only